Hyperphosphatemia Drugs are used in these patients to lower serum phosphate levels. A prolonged period of untreated hospital-acquired hyperphosphatemia can raise the risk of mortality from serious cardiovascular problems such congestive heart failure and death from arrhythmias.When receiving dialysis or other therapies for kidney illnesses, patients with chronic renal failure and kidney diseases frequently use Hyperphosphatemia Drugs in clinics. The medications support normal serum phosphate levels, lowering the risk of problems brought on by excessive phosphorus levels, such as a worsening of congestive heart failure symptoms.
A disorder called hyperphosphatemia is brought on by a high level of phosphate or phosphorous in the blood. The chemical phosphate, which contains the mineral phosphorous, is present in the body. The mineral phosphorus is crucial for the growth of teeth and bones as well as for converting food into body energy. The principal locations of phosphate in the body are the teeth, bones, cells, and in very little quantities, the blood. The kidneys have a role in controlling the body's phosphate levels.
These medicines can be utilized to cure individuals with a variety of renal problems, consisting chronic kidney disorders (CKD), diabetic ketoacidosis, and low parathyroid hormone levels. As per EKHA, around 100 million people in Europe suffer from CKD. The usage of phosphate binders for the therapy of individuals with chronic kidney disease has been proven to decrease hyperphosphatemia, lessen cardiac threat, and decrease bone scratches. Cardiac calcification in patient’s undergoing dialysis has been associated to arise the rate of fatality, and hyperphosphatemia drugs are known to contribute to this issue.
An electrolyte disease called hyperphosphatemia causes a high quantity of phosphate in the blood. Nearly 90% of people receiving dialysis for end-stage renal failure have this syndrome.
Read More @ http://cmiblogpost.weebly.com/blog/hyperphosphatemia-drugs-decreases-high-phosphate-levels
Iron-containing phosphate binders were under development for many years.
These non-calcium containing phosphate binders [(ferric citrate (Auryxia), lanthanum carbonate (Fosrenol), sevelamer carbonate (Renvela), sevelamer hydrochloride (Renagel), sucroferric oxyhydroxide (Velphoro)] are indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis or with ESRD.
Velphoro is a medicine used to control blood-phosphate levels in patients with long-term kidney disease and should be used with a low-phosphate diet and other treatments such as calcium and vitamin D supplements which help to control bone disease linked to kidney failure and high phosphate levels.
In September 2014, Auryxia (ferric citrate) was approved by the US FDA for the control of serum phosphorus levels in adults with CKD on dialysis.
Formulated as a chewable tablet, Fosrenol is available in 500mg, 750mg, and 1,000mg dosage strengths.
In March 2009, Fosrenol was launched in Japan.
